Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Netzsch Acquires Bruker Business

By Drug Discovery Trends Editor | September 7, 2012

The Netzsch analyzing & testing division and Bruker Corporation announced jointly that Netzsch Japan K.K. has acquired Bruker’s thermal analysis instruments business in Japan. Together with the well-established international Netzsch group, Netzsch Japan will further develop, produce, distribute and service the existing and new thermal analysis product lines.  Financial details of the transaction were not disclosed.

In Japan, Netzsch has previously been distributing its thermal analysis instruments via Bruker AXS K.K., headquartered in Yokohama.  Bruker has distributed high-end Netzsch thermal analysis products in Japan in parallel with Bruker’s routine thermal analysis product line.  Being one of the leading countries in top-level materials research and development, Japan is one of the most important markets for high-performance thermal analysis instrumentation.

Mr. Yoshio Shinoda, President of Netzsch Japan K.K., stated: “We are convinced that having a large R&D and production site that understands the needs of the Japanese market is an excellent way to further develop our future business in Japan.  With an additional 30 employees joining us from Bruker, Netzsch can now serve our Japanese customers even better, and we will further improve our outstanding reputation as the performance leader in thermal analysis instrumentation. This will boost the success that Netzsch has had in recent years in the Asia-Pacific region.”

Mr. Sadao Ueki, President of Bruker AXS K.K., added:  “It is a great benefit for our valued thermal analysis customers and employees to have the thermal analysis business now under the leadership and management of Netzsch Japan K.K, a global leader in high-performance thermal analysis instrumentation.  With the support of their headquarters in Germany, Netzsch will have a very successful future in Japan.”

Date: September 5, 2012
Source: Netzsch Analyzing & Testing


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE